中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2014年
24期
91-92,95
,共3页
肖承年%梁海山%黄鹏%奚振华
肖承年%樑海山%黃鵬%奚振華
초승년%량해산%황붕%해진화
老年脑梗死%疏血通%依达拉奉
老年腦梗死%疏血通%依達拉奉
노년뇌경사%소혈통%의체랍봉
Cerebral infarction in elderly patients%Shuxuetong%Edaravone
目的:分析疏血通联合依达拉奉治疗老年脑梗死的临床效果。方法选取89例老年脑梗死患者,将其根据用药方法不同划分为两组。两组均给予常规治疗,参照组49例患者加用依达拉奉治疗,静脉滴注30 mg,2次/d,研究组40例患者在参照组基础上加用疏血通治疗,6 ml/次,1次/d。两组均10 d为1个疗程,比较两组的治疗效果及不良反应情况。结果研究组治疗4、14 d后的ESS积分明显高于参照组(P<0.05);研究组的有效率为92.5%,明显高于参照组的81.6%(P<0.05);两组的不良反应发生率比较,差异无统计学意义(P>0.05),两组用药后有轻微不良反应,不需特殊处理,可自行消失。结论疏血通联合依达拉奉治疗老年脑梗死的效果显著,安全可靠,值得临床推广应用。
目的:分析疏血通聯閤依達拉奉治療老年腦梗死的臨床效果。方法選取89例老年腦梗死患者,將其根據用藥方法不同劃分為兩組。兩組均給予常規治療,參照組49例患者加用依達拉奉治療,靜脈滴註30 mg,2次/d,研究組40例患者在參照組基礎上加用疏血通治療,6 ml/次,1次/d。兩組均10 d為1箇療程,比較兩組的治療效果及不良反應情況。結果研究組治療4、14 d後的ESS積分明顯高于參照組(P<0.05);研究組的有效率為92.5%,明顯高于參照組的81.6%(P<0.05);兩組的不良反應髮生率比較,差異無統計學意義(P>0.05),兩組用藥後有輕微不良反應,不需特殊處理,可自行消失。結論疏血通聯閤依達拉奉治療老年腦梗死的效果顯著,安全可靠,值得臨床推廣應用。
목적:분석소혈통연합의체랍봉치료노년뇌경사적림상효과。방법선취89례노년뇌경사환자,장기근거용약방법불동화분위량조。량조균급여상규치료,삼조조49례환자가용의체랍봉치료,정맥적주30 mg,2차/d,연구조40례환자재삼조조기출상가용소혈통치료,6 ml/차,1차/d。량조균10 d위1개료정,비교량조적치료효과급불량반응정황。결과연구조치료4、14 d후적ESS적분명현고우삼조조(P<0.05);연구조적유효솔위92.5%,명현고우삼조조적81.6%(P<0.05);량조적불량반응발생솔비교,차이무통계학의의(P>0.05),량조용약후유경미불량반응,불수특수처리,가자행소실。결론소혈통연합의체랍봉치료노년뇌경사적효과현저,안전가고,치득림상추엄응용。
Objective To analyze clinical effect of shuxuetong combined with edaravone in the treatment of cerebral in-farction in elderly patients. Methods 89 elderly patients with cerebral infarction were selected and they were divided into the two groups based on different medication regimes.The routine treatment was given to the two groups,and 49 pa-tients in the reference group was intravenously given 30 mg of edaravone on the basis of the routine treatment,twice a day.40 patients in the research group was given 6 ml of Shuxuetong based on the treatment in the reference group,once a day.Patients of the two groups were continuously given the medication for 10 days as a treatment period,and the treat-ment effect and adverse reaction in the two groups were compared. Results ESS score after 4,14 days treatment in the research group were significantly higher than those in the control group (P<0.05);the effective rate in the research group (92.5%) was obviously higher than that in the reference group (81.6%) (P<0.05);there was no statistical difference of the incidence rate of adverse reaction in the two groups (P>0.05),minor adverse effects were detected in the two groups af-ter the medication, but they could disappear without special handling. Conclusion Shuxuetong combined with edar-avone in the treatment of cerebral infarction in elderly patients has a significant curative effect and is safe and reliable, which is worthy of clinical promotion and application.